Loading stock data…
Akari Therapeutics Plc (AKTX)
$10.51-0.22 (-2.05%)
Market OpenUpdated 12:26 PM EDT
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Akari Therapeutics, Plc in the Healthcare sector is trading at $10.73 with a market capitalization of $24M. Wall Street consensus targets $26.78 (1 analysts), implying a +149.6% move over the next 12 months. The stock is currently near its 52-week low of $3.02, remaining 30.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +149.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 27) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.63M↓ | -$3.23M↓ | -$2.22M↑ | -$3.12M↑ | -$3.52M |
| Net Income | -$14.46M↓ | -$5.30M↑ | -$6.40M↓ | -$1.90M↑ | -$3.71M |
Peer Comparison
JNJUNHPFE
Fundamentals
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell ki...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$23.62M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-195.05%
Volume
Today's trading volume
45,413
Recent News
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
European equities traded in the US as American depositary receipts were lower late Wednesday morning
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Tuesday Trading
European equities traded in the US as American depositary receipts were tracking sharply lower late
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
European equities traded in the US as American depositary receipts were sharply higher late Wednesda
European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading
European equities traded in the US as American depositary receipts started the week significantly hi
European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week
European equities traded in the US as American depositary receipts were trending higher late Friday